Close Menu

NEW YORK – Inflammatix on Friday announced that it had raised $32 million in Series C financing to advance its rapid HostDx tests through commercial launch in Europe and submission for clearance to the US Food and Drug Administration in 2021.

The funding round included participation from existing investors Khosla Ventures, Northpond Ventures, and Think.Health Ventures, and new investors that included Grey Sky Venture Partners.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.